---
title: "Genentech nabs approval for Evrysdi tablet for spinal muscular atrophy"
date: "2025-02-12 20:21:57"
summary: "The U.S. FDA has approved a tablet version of Roche (OTCQX:RHHBY) unit Genentech's Evrysdi (risdiplam) for spinal muscular atrophy. Genentech said the oral medicine is the only non-invasive, disease-modifying treatment for the condition. An oral solution version of Evrysdi was approved in 2020. A bioequivalence study used to support approval..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1193973033/image_1193973033.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* The U.S. FDA has approved a tablet version of Roche ([OTCQX:RHHBY](https://seekingalpha.com/symbol/RHHBY "Roche Holding AG")) unit Genentech's Evrysdi (risdiplam) for spinal muscular atrophy.
* Genentech [said](https://seekingalpha.com/pr/20000312-fda-approves-genentech-s-evrysdi-tablet-as-first-and-only-tablet-for-spinal-muscular-atrophy "said") the oral medicine is the only non-invasive, disease-modifying treatment for the condition.
* An oral solution version of Evrysdi was approved in 2020. A bioequivalence study used to support approval found that the tablet has the same efficacy and safety as the oral solution.

[seekalpha](https://seekingalpha.com/news/4407006-genentech-nabs-approval-evrysdi-tablet-spinal-muscular-atrophy)
